You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

IDO1

Showing 1 - 25 of 193
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma, Stage 0a Bladder Cancer AJCC v8, Stage 0is Bladder Cancer AJCC v8

Not yet recruiting
  • High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma
  • +3 more
  • PD-L1/IDO Peptide Vaccine
  • Pembrolizumab
  • Sacramento, California
    University of California Davis Comprehensive Cancer Center
Apr 24, 2023

Metastatic Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8

Active, not recruiting
  • Metastatic Hepatocellular Carcinoma
  • +7 more
  • IDO1 Inhibitor BMS-986205
  • Nivolumab
  • Sacramento, California
    University of California Davis Comprehensive Cancer Center
Dec 16, 2021

Metastatic Melanoma Trial in Herlev (Nivolumab, PD-L1/IDO peptide vaccine)

Recruiting
  • Metastatic Melanoma
  • Herlev, Denmark
  • +1 more
Mar 15, 2022

Lip, Oral Cavity Squamous Cell Carcinoma, Pharynx Trial in Columbus, Philadelphia (biological, procedure, other)

Recruiting
  • Lip
  • +4 more
  • Nivolumab
  • +3 more
  • Columbus, Ohio
  • +1 more
Oct 25, 2021

Fallopian Tube Carcinoma, Ovarian Carcinoma, Primary Peritoneal Carcinoma Trial in Buffalo (biological, drug, other)

Completed
  • Fallopian Tube Carcinoma
  • +2 more
  • DEC-205/NY-ESO-1 Fusion Protein CDX-1401
  • +4 more
  • Buffalo, New York
    Roswell Park Cancer Institute
Jul 20, 2021

Advanced Cancer Trial in Worldwide (Relatlimab, Nivolumab, BMS-986205)

Recruiting
  • Advanced Cancer
  • Relatlimab
  • +3 more
  • Duarte, California
  • +23 more
Oct 24, 2022

NSCLC, Progression of NSCLC, NSCLC Recurrent Trial in Saint Louis, Cincinnati (Docetaxel, Tergenpumatucel-L, Indoximod)

Terminated
  • Non-small Cell Lung Cancer
  • +2 more
  • Saint Louis, Missouri
  • +1 more
Apr 4, 2022

Glioblastoma Trial in Chicago (biological, radiation, drug)

Recruiting
  • Glioblastoma
  • IDO1 Inhibitor BMS-986205
  • +3 more
  • Chicago, Illinois
    Northwestern University
Jun 30, 2020

Allogeneic Hematopoietic Stem Cell Transplantation Recipient Trial in Columbus (Vitamin A Compound)

Recruiting
  • Allogeneic Hematopoietic Stem Cell Transplantation Recipient
  • Vitamin A Compound
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Mar 24, 2022

Glioblastoma, Glioblastoma Multiforme Trial in Baltimore (Nivolumab, Anti-GITR Monoclonal Antibody MK-4166, IDO1 inhibitor

Terminated
  • Glioblastoma
  • Glioblastoma Multiforme
  • Baltimore, Maryland
    Johns Hopkins University/Sidney Kimmel Cancer Center
Jun 30, 2020

Endometrial Adenocarcinoma, Endometrial Carcinosarcoma Trial in United States (Nivolumab, BMS- 986205)

Active, not recruiting
  • Endometrial Adenocarcinoma
  • Endometrial Carcinosarcoma
  • Basking Ridge, New Jersey
  • +6 more
Nov 29, 2021

Gastrointestinal Stromal Tumors Trial in Ann Arbor, New York (Pembrolizumab, Epacadostat)

Completed
  • Gastrointestinal Stromal Tumors
  • Ann Arbor, Michigan
  • +1 more
Mar 18, 2021

Solid Tumor Trial in Gainesville, Saint Louis, Albuquerque (NLG802)

Completed
  • Solid Tumor
  • Gainesville, Florida
  • +2 more
Jun 3, 2020

Breast Cancer, Lung Cancer, Melanoma Trial in Nashville (1-methyl-D-tryptophan)

Terminated
  • Breast Cancer
  • +4 more
  • Nashville, Tennessee
    Vanderbilt University
May 26, 2020

Solid Tumor, Non Small Cell Lung Cancer, Renal Cell Carcinoma Trial in Worldwide (LY3381916, LY3300054)

Terminated
  • Solid Tumor
  • +3 more
  • Indianapolis, Indiana
  • +11 more
Jun 8, 2020

Stage III Fallopian Tube Cancer AJCC v7, Stage III Ovarian Cancer AJCC v6 and v7, Stage III Primary Peritoneal Cancer AJCC v7

Active, not recruiting
  • Stage III Fallopian Tube Cancer AJCC v7
  • +14 more
  • Minneapolis, Minnesota
  • +1 more
Jan 27, 2023

Melanoma Stage III, Melanoma Stage IV Trial in Boston (Nivolumab, BMS-986205, Ipilimumab)

Withdrawn
  • Melanoma Stage III
  • Melanoma Stage IV
  • Boston, Massachusetts
  • +1 more
Feb 3, 2020

Metastatic Melanoma, Stage III Melanoma, Stage IV Melanoma Trial in United States (Indoximod, Ipilimumab, Nivolumab)

Completed
  • Metastatic Melanoma
  • +2 more
  • Augusta, Georgia
  • +5 more
Jun 3, 2020

Glioblastoma Multiforme, Glioma, Gliosarcoma Trial in United States (Indoximod, Temozolomide, Conformal Radiation)

Completed
  • Glioblastoma Multiforme
  • +7 more
  • Aurora, Colorado
  • +4 more
Jun 3, 2020

Advanced Solid Tumors Trial in Pittsburgh (Stereotactic Body Radiotherapy (SBRT), navoximod, NLG802 (indoximod Prodrug))

Not yet recruiting
  • Advanced Solid Tumors
  • Stereotactic Body Radiotherapy (SBRT)
  • +2 more
  • Pittsburgh, Pennsylvania
    UPMC Hillman Cancer Center
Jul 18, 2022

Metastatic Pancreatic Adenocarcinoma, Metastatic Pancreatic Cancer Trial in United States (Nab-Paclitaxel, Gemcitabine,

Completed
  • Metastatic Pancreatic Adenocarcinoma
  • Metastatic Pancreatic Cancer
  • Palo Alto, California
  • +10 more
May 26, 2020

Patient Satisfaction Trial in Tel HaShomer (virtual reality headset, colonoscopy with standard sedation.)

Recruiting
  • Patient Satisfaction
  • virtual reality headset
  • colonoscopy with standard sedation.
  • Tel HaShomer, Israel
    Gastroenterology department, Sheba Medical Center
Jan 26, 2023

Metastatic Prostate Cancer, Prostate Cancer, Prostate Tumor Trial run by the NCI (M7824, N-803, MVA-BN-Brachyury)

Recruiting
  • Metastatic Prostate Cancer
  • +4 more
  • M7824
  • +4 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 20, 2023

ATM Gene Mutation, Deleterious BRCA1 Gene Mutation, Deleterious BRCA2 Gene Mutation Trial (Epacadostat, Pembrolizumab)

Withdrawn
  • ATM Gene Mutation
  • +9 more
  • (no location specified)
May 28, 2019

Skin Restricted Lupus, Psychiatric Disorders Trial in Clermont-Ferrand (Biological dosage from plasma)

Completed
  • Skin Restricted Lupus
  • Psychiatric Disorders
  • Biological dosage from plasma
  • Clermont-Ferrand, France
    CHU Clermont-Ferrand
Jan 5, 2023